Sensorion SA (ALSEN.PA)
EUR 0.64
(-6.16%)
EUR 0.64
(-6.16%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.86 Million EUR | -23.79% |
| 2022 | 3.76 Million EUR | -5.56% |
| 2021 | 3.98 Million EUR | 2.65% |
| 2020 | 3.88 Million EUR | -81.48% |
| 2019 | 20.96 Million EUR | 192743.65% |
| 2018 | 10.87 Thousand EUR | -97.09% |
| 2017 | 374 Thousand EUR | -61.65% |
| 2016 | 975.35 Thousand EUR | -46.3% |
| 2015 | 1.81 Million EUR | 201.48% |
| 2014 | 602.45 Thousand EUR | -59.48% |
| 2013 | 1.48 Million EUR | 0.0% |
| 2012 | - EUR | -100.0% |
| 2011 | 43.00 EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.64 Million EUR | 0.0% |
| 2023 Q4 | 2.86 Million EUR | 0.0% |
| 2023 Q2 | 3.2 Million EUR | 0.0% |
| 2023 FY | 2.86 Million EUR | -23.79% |
| 2022 Q4 | 3.76 Million EUR | 0.0% |
| 2022 Q2 | 3.78 Million EUR | 0.0% |
| 2022 FY | 3.76 Million EUR | -5.56% |
| 2021 Q4 | 3.98 Million EUR | 0.0% |
| 2021 FY | 3.98 Million EUR | 2.65% |
| 2021 Q2 | 3.8 Million EUR | 0.0% |
| 2020 Q2 | 923.03 Thousand EUR | 0.0% |
| 2020 FY | 3.88 Million EUR | -81.48% |
| 2020 Q4 | 3.88 Million EUR | 0.0% |
| 2019 Q2 | 19.96 Million EUR | 0.0% |
| 2019 Q4 | 20.96 Million EUR | 0.0% |
| 2019 FY | 20.96 Million EUR | 192743.65% |
| 2018 FY | 10.87 Thousand EUR | -97.09% |
| 2018 Q2 | 11.4 Thousand EUR | 0.0% |
| 2018 Q4 | 10.87 Thousand EUR | 0.0% |
| 2017 Q2 | 4.67 Million EUR | 0.0% |
| 2017 FY | 374 Thousand EUR | -61.65% |
| 2017 Q4 | 2.23 Million EUR | 0.0% |
| 2016 Q2 | 641.00 EUR | 0.0% |
| 2016 Q4 | 872.45 Thousand EUR | 0.0% |
| 2016 FY | 975.35 Thousand EUR | -46.3% |
| 2015 FY | 1.81 Million EUR | 201.48% |
| 2015 Q4 | 2.55 Million EUR | 0.0% |
| 2015 Q2 | 600 Thousand EUR | 0.0% |
| 2014 FY | 602.45 Thousand EUR | -59.48% |
| 2014 Q4 | 602.45 Thousand EUR | 0.0% |
| 2013 FY | 1.48 Million EUR | 0.0% |
| 2012 FY | - EUR | -100.0% |
| 2011 FY | 43.00 EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | 15.375% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 94.828% |
| Adocia SA | 13.08 Million EUR | 78.081% |
| Aelis Farma SA | 4.03 Million EUR | 28.955% |
| Biophytis S.A. | 8.27 Million EUR | 65.311% |
| Advicenne S.A. | 17.42 Million EUR | 83.536% |
| genOway Société anonyme | 7.23 Million EUR | 60.34% |
| IntegraGen SA | 1.12 Million EUR | -155.063% |
| Medesis Pharma S.A. | 1.2 Million EUR | -139.066% |
| Neovacs S.A. | 650 Thousand EUR | -341.352% |
| NFL Biosciences SA | 62.17 Thousand EUR | -4514.126% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 34.149% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -5.593% |
| Theranexus Société Anonyme | 3.64 Million EUR | 21.253% |
| TME Pharma N.V. | 1.16 Million EUR | -146.037% |
| Valbiotis SA | 6.87 Million EUR | 58.29% |
| TheraVet SA | 1.15 Million EUR | -147.338% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | 68.118% |
| argenx SE | 18.1 Million EUR | 84.155% |
| BioSenic S.A. | 28.16 Million EUR | 89.813% |
| Celyad Oncology SA | 902 Thousand EUR | -218.047% |
| DBV Technologies S.A. | 13.01 Million USD | 77.964% |
| Galapagos NV | 9.59 Million EUR | 70.104% |
| Genfit S.A. | 70.17 Million EUR | 95.912% |
| GeNeuro SA | 7.73 Million EUR | 62.925% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | 45.811% |
| Innate Pharma S.A. | 39.89 Million EUR | 92.809% |
| Inventiva S.A. | 37.4 Million EUR | 92.331% |
| MaaT Pharma SA | 14.07 Million EUR | 79.618% |
| MedinCell S.A. | 58.96 Million EUR | 95.134% |
| Nanobiotix S.A. | 50.56 Million EUR | 94.327% |
| Onward Medical N.V. | 16.87 Million EUR | 82.999% |
| Oryzon Genomics S.A. | 13.68 Million EUR | 79.04% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 93.736% |
| Oxurion NV | 12.33 Million EUR | 76.741% |
| Pharming Group N.V. | 155.29 Million EUR | 98.153% |
| Poxel S.A. | 46.9 Million EUR | 93.883% |
| GenSight Biologics S.A. | 18.42 Million EUR | 84.432% |
| Transgene SA | 1.25 Million EUR | -128.225% |
| Financière de Tubize SA | 79.2 Million EUR | 96.378% |
| UCB SA | 3.03 Billion EUR | 99.906% |
| Valneva SE | 208.81 Million EUR | 98.626% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -7449.439% |